Xencor Inc (XNCR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$26.61-0.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · XNCR
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | 105.0 | 125.6 | 110.5 | 174.6 | 164.6 | 275.1 | 122.7 | 156.7 | 40.6 | — | — | — | — |
| Operating Expenses & Income | |||||||||||||
| R&D Expenses | 255.8 | 239.4 | 227.7 | 253.6 | 199.6 | 192.5 | 169.8 | 118.6 | 97.5 | 71.8 | 51.9 | 34.1 | 18.5 |
| Operating Income | (216.1) | (177.5) | (178.4) | (132.4) | (82.5) | 43.8 | (76.8) | 13.8 | (79.4) | (43.1) | 44.0 | (18.3) | (16.5) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | 31.9 | 36.6 | 6.2 | 0.0 | 0.0 | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest & Investment Income | 23.0 | 27.5 | — | 19.3 | 4.8 | 0.9 | — | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | (13.2) | (4.8) | (0.8) | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 55.2 | 87.9 | (56.5) | 12.7 | 28.0 | 38.9 | 7.5 | 13.4 | 9.0 | 4.2 | 2.1 | 0.7 | 0.0 |
| Asset Writedown | — | 9.2 | — | 0.0 | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (160.8) | (89.6) | (234.9) | (119.6) | (54.5) | 82.6 | (69.3) | 27.2 | (70.4) | (38.9) | 46.1 | — | — |
| Income Tax Expense | 2.5 | 2.5 | 1.6 | 13.7 | 0.7 | 0.0 | 0.0 | 0.3 | (0.5) | (0.5) | 1.0 | — | — |
| Net Income | |||||||||||||
| Minority Interest | — | (0.2) | (3.9) | (0.2) | 0.0 | 0.0 | — | — | — | — | — | — | — |
| Net Income | (163.3) | (91.9) | (232.6) | (133.1) | (55.2) | 82.6 | (69.3) | 26.9 | (70.4) | (38.5) | 45.1 | (17.6) | (16.4) |
| Per Share | |||||||||||||
| Basic EPS | (2.15) | (1.24) | (3.58) | (2.20) | (0.93) | 1.42 | (1.21) | 0.48 | (1.31) | (0.82) | 1.09 | (0.45) | (0.52) |
| Diluted EPS | (2.15) | (1.24) | (3.58) | (2.20) | (0.93) | 1.37 | (1.21) | 0.46 | (1.31) | (0.82) | 1.07 | (0.45) | (0.52) |
| Revenue per Share | 1.38 | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 75.9 | 74.2 | 65.0 | 60.5 | 59.7 | 58.4 | 57.2 | 56.5 | 53.9 | 46.8 | 41.3 | 39.0 | 31.4 |
| Diluted Weighted Avg Shares | 75.9 | 74.2 | 65.0 | 60.5 | 59.7 | 60.5 | 57.2 | 58.5 | 53.9 | 46.8 | 42.4 | 39.0 | 31.4 |
| Supplemental | |||||||||||||
| EBITDA | — | (167.9) | (167.6) | (122.3) | (75.1) | 50.1 | (72.1) | 17.2 | (77.0) | (41.9) | 45.5 | (17.2) | (15.6) |
| EBIT | (216.1) | (177.5) | (178.4) | (132.4) | (82.5) | 43.8 | (76.8) | 13.8 | (79.4) | (43.1) | 44.0 | (18.3) | (16.5) |
| Effective Tax Rate | -1.5% | — | — | -11.4% | -1.2% | 0.0% | 0.0% | 1.1% | 0.7% | 1.2% | 2.1% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.